Abstract
Although conventional high-throughput screens performed in vitro with purified protein kinases are powerful tools to discover new kinase inhibitors, they are far from ideal for determining efficacy in vivo. As a complementary approach, cell-based, targetdriven secondary screens may help predict in vivo compound potency and specificity as well as evaluate bioavailability and toxicity. Here the authors report a simple protocol for treating K562 Bcr-Abl-expressing cells with small-molecule kinase inhibitors in 96-well filter-bottom plates followed by in-plate cell lysis. The lysates were assayed via a solid-phase kinase assay, allowing determination of apparent IC 50 for known Bcr-Abl inhibitors as well as facilitating the screening of a small kinase inhibitor library. This approach may have further applications in generating lysates for analyzing kinase activity and inhibition in other nonadherent suspension cell lines. © 2010 Society for Biomolecular Sciences.
Author supplied keywords
Cite
CITATION STYLE
Mand, M. R., Wu, D., Veach, D. R., & Kron, S. J. (2010). Cell Treatment and Lysis in 96-Well Filter-Bottom Plates for Screening Bcr-Abl Activity and Inhibition in Whole-Cell Extracts. Journal of Biomolecular Screening, 15(4), 434–440. https://doi.org/10.1177/1087057110363307
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.